Core Viewpoint - Korn/Ferry (KFY) is expected to report quarterly earnings of $1.24 per share, reflecting a 5.1% increase year-over-year, with revenues projected at $685.13 million, a 1.5% increase compared to the previous year [1]. Group 1: Earnings and Revenue Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating analysts' reassessment of their projections [1]. - Analysts predict 'Fee Revenue- Total Executive search' to be $217.22 million, showing a year-over-year increase of 4.1% [4]. - The average estimate for 'Fee Revenue' stands at $685.03 million, indicating a 1.5% increase from the prior-year quarter [4]. - 'Fee Revenue- Digital' is expected to reach $89.03 million, reflecting a 1% increase from the year-ago quarter [4]. - 'Fee Revenue- Consulting' is projected to be $162.60 million, indicating a decrease of 3.1% from the prior-year quarter [5]. Group 2: Market Performance - Over the past month, shares of Korn/Ferry have returned 4.4%, outperforming the Zacks S&P 500 composite's 3.6% change [5]. - Korn/Ferry currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [5].

Core Viewpoint - IO Biotech, Inc. (IOBT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - A strong correlation exists between changes in earnings estimates and near-term stock price movements, largely due to institutional investors adjusting their valuations based on these estimates [4][6]. Company Performance and Investor Sentiment - The upgrade for IO Biotech suggests an improvement in the company's underlying business, which could lead to increased buying pressure and a rise in stock price [5][10]. - Over the past three months, the Zacks Consensus Estimate for IO Biotech has increased by 1%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7][9]. - IO Biotech's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Viewpoint - Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2]. - The recent upgrade for Biodexa Pharmaceuticals suggests an improvement in its earnings outlook, which could lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - There is a strong correlation between changes in earnings estimates and near-term stock price movements, with institutional investors using these estimates to determine fair value [5][7]. - Biodexa Pharmaceuticals has seen a 90% increase in its Zacks Consensus Estimate over the past three months, indicating a positive trend in earnings expectations [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of generating significant returns for top-rated stocks [8][10]. - The upgrade to Zacks Rank 2 places Biodexa in the top 20% of Zacks-covered stocks, suggesting it is well-positioned for potential market-beating returns in the near term [11].

Core Viewpoint - AirSculpt Technologies, Inc. (AIRS) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4][6]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2][3]. - The recent upgrade for AirSculpt Technologies suggests an improvement in its underlying business, which is expected to lead to increased stock prices due to investor interest [4][6]. Impact of Earnings Estimate Revisions - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly influenced by institutional investors [5][7]. - For AirSculpt Technologies, the Zacks Consensus Estimate has increased by 11.1% over the past three months, reflecting a positive trend in earnings estimates [9]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [8][10]. - AirSculpt Technologies' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].

Core Viewpoint - Elastic (ESTC) shares have increased by 6.2% recently, with a mean price target of $119.83 suggesting a potential upside of 40.8% from the current price of $85.09 [1] Price Targets and Analyst Estimates - The mean estimate consists of 24 short-term price targets with a standard deviation of $13.6, indicating variability among analysts [2] - The lowest estimate is $87.00, suggesting a 2.2% increase, while the highest estimate is $150.00, indicating a potential surge of 76.3% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [7] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [9] - The Zacks Consensus Estimate for the current year has risen by 1.6% over the past month, with two estimates increasing and no negative revisions [10] - ESTC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - While price targets are often sought after, they can mislead investors and should not be the sole basis for investment decisions [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

Group 1: Stock Performance and Price Targets - Shares of Build-A-Bear (BBW) have increased by 15.9% over the past four weeks, closing at $59.63, with a mean price target of $80 indicating a potential upside of 34.2% [1] - The average price target ranges from a low of $75.00 to a high of $85.00, with a standard deviation of $5, suggesting a potential increase of 25.8% to 42.6% from the current price level [2] Group 2: Analyst Sentiment and Earnings Estimates - Analysts show strong agreement on BBW's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, three earnings estimates for BBW have been revised higher, leading to a 5% increase in the Zacks Consensus Estimate [10] - BBW holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Group 3: Price Target Reliability - While price targets are commonly referenced by investors, they can often mislead, as empirical research indicates that they rarely predict actual stock price movements [5][6] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price direction, serving as a starting point for further research [7]

Group 1 - CorMedix (CRMD) shares have increased by 21.4% over the past four weeks, closing at $14.64, with a mean price target of $19.33 indicating a potential upside of 32% [1] - The average price targets from analysts range from a low of $17.00 to a high of $21.00, with a standard deviation of $1.37, suggesting a relatively high agreement among analysts [2] - Analysts are optimistic about CRMD's earnings prospects, as indicated by a 53.6% increase in the Zacks Consensus Estimate for the current year over the past month [10][11] Group 2 - The Zacks Rank for CRMD is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, supporting the expectation of an upside in CRMD [9]

Core Viewpoint - OppFi Inc. (OPFI) shows potential for significant upside, with a mean price target of $14 indicating a 36.1% increase from the current price of $10.29 [1] Price Target Analysis - The average price target consists of three estimates ranging from $12.50 to $16.00, with a standard deviation of $1.8, suggesting a variability in analyst predictions [2] - The lowest estimate indicates a 21.5% increase, while the highest suggests a 55.5% upside [2] - A low standard deviation indicates a strong agreement among analysts regarding the price movement direction [7] Earnings Estimates - Analysts are optimistic about OPFI's earnings prospects, with a consensus indicating higher earnings estimates compared to previous predictions [4][9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 15.5%, with two estimates moving higher and no negative revisions [10] Zacks Rank - OPFI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of OPFI's potential gains, it does provide a useful guide for the direction of price movement [12]

Group 1: Stock Performance and Price Targets - Shares of Marex Group PLC (MRX) have gained 0.1% over the past four weeks, closing at $35.36, with a mean price target of $50.89 indicating a potential upside of 43.9% [1] - The average of nine short-term price targets ranges from a low of $36.00 to a high of $58.00, with a standard deviation of $6.37, suggesting a potential increase of 1.8% to 64% from the current price [2] Group 2: Analyst Consensus and Earnings Estimates - There is strong agreement among analysts regarding the company's ability to report better earnings, which supports the view of potential upside [4] - The Zacks Consensus Estimate for the current year has increased by 2.7% due to one estimate moving higher over the last 30 days, with no negative revisions [10] - MRX currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Group 3: Price Target Reliability - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][5] - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [6] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts about the stock's price movement direction [7]

Core Viewpoint - XOMA Royalty (XOMA) shares have increased by 22.2% in the past four weeks, closing at $34.76, with a potential upside of 86.1% based on Wall Street analysts' mean price target of $64.67 [1] Price Targets - The average price targets range from a low of $35.00 to a high of $104.00, with a standard deviation of $35.5, indicating variability among analysts [2] - The lowest estimate suggests a 0.7% increase from the current price, while the highest estimate indicates a potential upside of 199.2% [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about XOMA's earnings, with a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][9] - The Zacks Consensus Estimate for the current year has surged by 3671.4% over the past month, with three estimates revised upward and no negative revisions [10] Zacks Rank - XOMA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, and reliance solely on them may not yield satisfactory returns [5][8]